Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,850 GBX | +0.71% |
|
+2.21% | +3.41% |
24/06 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
20/06 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.41% | 5.29B | |
+62.22% | 856B | |
+38.95% | 631B | |
-4.06% | 359B | |
+15.52% | 325B | |
+9.43% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+16.26% | 177B | |
+2.43% | 165B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Transcript : Hikma Pharmaceuticals PLC Presents at JP Morgan 37th Annual Healthcare conference, Jan-08-2019 08